Quick Answer
Celldex Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $28.87 million for the year ending 2025.
- Celldex Therapeutics, Inc. showed an increase of +1.8% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Celldex Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2008 to 2025), Celldex Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 34.8%.
- Historical annual values: Fiscal year 2025: $28.87 million | Fiscal year 2024: $28.36 million | Fiscal year 2023: $34.81 million | Fiscal year 2022: $29.43 million | Fiscal year 2021: $39.14 million | Fiscal year 2020: $43.84 million | Fiscal year 2019: $11.23 million | Fiscal year 2018: $24.31 million | Fiscal year 2017: $40.29 million | Fiscal year 2016: $42.46 million | Fiscal year 2015: $72.11 million | Fiscal year 2014: $28.02 million | Fiscal year 2013: $169.40 million | Fiscal year 2012: $24.90 million | Fiscal year 2011: $11.90 million | Fiscal year 2010: $21.29 million | Fiscal year 2009: $57.00 million | Fiscal year 2008: $44.26 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: